RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $85

Benzinga · 3d ago
RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $100 to $85.